Regulation - Research, Bayer


Current filters:


Popular Filters

FDA lifts partial clinical hold on OncoMed's ipafricept


Shares of US biotech companies OncoMed Pharmaceuticals rose 5.6% to $17.68 on news that the US Food and…

BayerBiotechnologyipafriceptOncologyOncoMed PharmaceuticalsRegulationResearchUSA

“Breakthrough Therapy” status for Portola’s andexanet alfa


USA-based Portola Pharmaceuticals has been granted “Breakthrough Therapy” designation by the US Food…

andexanet alfaBayerBristol-Myers SquibbCardio-vascularEliquisNorth AmericaPharmaceuticalPortola PharmaceuticalsRegulationResearchXarelto

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

News briefs: US priority review for regorafenib; Ph IIb blisibimod data


Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Bayer cancer drug candidate regorafenib improves survival in GIST


German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…


Strong results for Bayer's Xarelto in treating pulmonary blood clots


German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Bayer to file for EU approval of aflibercept for central retinal vein occlusion


German drug major Bayer (BAY: DE) says that it will file for European approval of its macular edema treatment…


Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain


German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival…

AlgetaAlmirallAlpharadinBayerCardio-vascularEuropeMarkets & MarketingOncologyPharmaceuticalRegulationResearchXarelto

Back to top